key: cord-0911413-5kmtoyk0
authors: White, P Lewis; Dhillon, Rishi; Cordey, Alan; Hughes, Harriet; Faggian, Federica; Soni, Shuchita; Pandey, Manish; Whitaker, Harriet; May, Alex; Morgan, Matt; Wise, Matthew P; Healy, Brendan; Blyth, Ian; Price, Jessica S; Vale, Lorna; Posso, Raquel; Kronda, Joanna; Blackwood, Adam; Rafferty, Hannah; Moffitt, Amy; Tsitsopoulou, Alexandra; Gaur, Soma; Holmes, Tom; Backx, Matthijs
title: A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU
date: 2020-08-29
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1298
sha: 6b1943e2e98aaa502d694253351d314557c688fb
doc_id: 911413
cord_uid: 5kmtoyk0

BACKGROUND: Fungal co-infection is a recognised complication of respiratory virus infections, increasing morbidity and mortality, but can be readily treated if diagnosed early. An increasing number of small studies describing aspergillosis in COVID-19 patients with severe respiratory distress are being reported, but comprehensive data is lacking. The aim of this study was to determine the incidence, risk factors and impact of invasive fungal disease in adult COVID-19 patients with severe respiratory distress. METHODS: An evaluation of a national, multi-centre, prospective cohort evaluation of an enhanced testing strategy to diagnose invasive fungal disease in COVID-19 intensive care patients. Results were used to generate a mechanism to define aspergillosis in future COVID-19 patients. RESULTS: One-hundred and thirty-five adults (median age: 57, M/F: 2·2/1) were screened. The incidence was 26.7% (14.1% aspergillosis, 12·6% yeast infections). The overall mortality rate was 38%; 53% and 31% in patients with and without fungal disease, respectively (P: 0.0387). The mortality rate was reduced by the use of antifungal therapy (Mortality: 38·5% in patients receiving therapy versus 90% in patients not receiving therapy (P: 0.008). The use of corticosteroids (P: 0.007) and history of chronic respiratory disease (P: 0.05) increased the likelihood of aspergillosis. CONCLUSIONS: Fungal disease occurs frequently in critically ill, mechanically ventilated COVID-19 patients. The survival benefit observed in patients receiving antifungal therapy implies that the proposed diagnostic and defining criteria are appropriate. Screening using a strategic diagnostic approach and antifungal prophylaxis of patients with risk factors will likely enhance the management of COVID-19 patients.

The emergence of the novel coronavirus COVID-19 has placed a major strain on healthcare services globally, and efforts are focussed on the management of this disease. Secondary infections, including invasive pulmonary aspergillosis (IPA), are a recognised complication of respiratory virus infections. [1] A strong association has been observed in patients presenting with acute respiratory failure due to influenza (IAPA incidence: 19%), possibly a result of damage to epithelial cells and/or immune dysregulation. [2] [3] An increased incidence of IPA in those suffering with severe respiratory virus infection has led to concerns that this may also occur in patients with acute respiratory failure due to infection, particularly as this infection causes pulmonary damage and an inflammatory environment permissive for fungal infection. [4] [5] [6] [7] [8] However, data on COVID-19 associated IPA (CAPA) are currently limited to anecdotal reports or small case studies. Larger studies are needed to determine an accurate incidence, optimize diagnostics and improve patient management. [9] [10] [11] [12] [13] [14] [15] The Public Health Wales Mycology Reference Centre has 20 years' experience of using non-culture fungal diagnostics to assist in the management of patients at risk of invasive fungal disease (IFD).

[16] Given the urgent need for evidence to guide diagnostic and antimicrobial prescribing policy, a testing strategy to diagnose IFD in critically-ill COVID-19 patients across Wales was recommended with aim of determining the incidence, impact and risk factors ( Figure 1 ). This manuscript describes the findings and is, to our knowledge, the first national, prospective screening of PCR confirmed COVID-19 patients for IFD, incorporating novel diagnostics.

A c c e p t e d M a n u s c r i p t 4

Enhanced mycological testing of intensive care unit (ICU) patients with refractory severe respiratory illness or deterioration of respiratory function one week post-COVID diagnosis was recommended.

The optimum strategy, in line with recent international opinion, involved obtaining both blood and deep respiratory samples for mycological investigation of both yeast and mold infections (Figure 1 ). [6] To enhance the detection of yeast infection, blood culture was combined with (1-3)-β-D-Glucan (BDG) testing, the latter also of benefit for the diagnosis of IPA, when combined with molecular, antigen and culture investigation of respiratory samples. The service was available to all ICUs across Wales with samples sent as part of the routine investigations for COVID-19-associated secondary infections. Antifungal therapy (AFT) was administered at the clinicians' discretion. The appropriateness of AFT was determined by considering the type of IFD diagnosed (yeast or mold infection), the degree of identification when the first AFT wad administered and how this related in international therapy guidelines. All data generated and interpreted was part of routine patient management, forming a prospective, consecutive cohort study covering the first seven weeks of service, with one-month follow-up, not requiring ethical approval.

Novel definitions, their justification for classifying CAPA and comparison with previous definitions used to classify IPA in the ICU are described in Table 1 . Novel definitions are in line with recent opinion, stratifying the confidence of IPA diagnosis according to the degree of clinical/mycological evidence. [6] 

Samples were tested by the BioRad Aspergillus Ag assay (GM-EIA) (BioRad, Hemel Hempstead, UK) following manufacturer's instructions, using a positivity threshold of ≥0·5 in serum and ≥1·0 in deep respiratory samples (non-directed bronchial lavage (NBL) or bronchoalveolar lavage (BAL)).

Aspergillus PCR testing was performed on 0·5ml serum/plasma and NBL/BAL, following international A c c e p t e d M a n u s c r i p t 5 recommendations, using the BioMerieux Emag extractor, with a well validated "in-house" Q-PCR assay performed on the Qiagen Rotorgene Q-HRM . [17,18] Serum BDG was detected using the Fungitell assay (Associates of Cape Cod, Liverpool, UK) following manufacturer's instructions, with a positivity threshold of 80pg/ml. Samples were tested in duplicate and the mean value used for interpretation.

Blood and central venous catheter culture was performed following national guidance for investigating sepsis, with 5-10ml of blood incubated up to 10 days on the BD Bactec FX Automated Blood Culture Analyser.

[19] Yeast were identified using the Bruker MALDI-TOF system.

Radiological investigations were performed at the clinicians' discretion. The investigations included computed tomography of the thorax (CT-Thorax), with or without high-resolution enhancement, and CT-pulmonary angiogram (CTPA). Data was retrieved from prospective reports generated by the consultant radiologist, no independent analysis was performed. Radiological evidence such as nodules, halos, cavities, wedge shaped, lobar or segmental consolidation and tree in bud presentation were recorded as evidence typical of IPA, given these findings are not usually associated with COVID-19 infection and following well-established international definitions for IFD.

[20, 21] All other evidence of chest infection was considered non-specific. Alternative reasons for the chest radiology considered typical of IPA was documented. Given sinusitis is a frequent presentation of aspergillosis, evidence of sinusitis on CT head/sinus was recorded but not deemed typical of CAPA, due its presence in ventilated and/or COVID-19 patients. Due to the lack of bronchoscopic investigation it was not possible identify mucosal plaques suggestive of Aspergillus tracheobronchitis, evident in IAPA. [2] A c c e p t e d M a n u s c r i p t 6

The positivity rate for each test was determined for both specimens and patients. For proportionate values ninety-five percent confidence intervals and, where required, P values (Fishers exact test; P: 0·05) were generated to determine significance. Median values were compared using a Mann-Whitney T-test for pairwise analysis when comparing multiple median values. Associations between clinical factors were determined for combined IFD, and IPA and candidosis individually.

Over the period, 257 patients were admitted to Welsh ICUs with COVID-19 infection. Fifty-three percent (135 patients) were screened for IFD, 123 patients had blood cultures and BDG testing performed, 60 patients had a NBL tested, and 48 of these patients had all tests ( Figure 1 ). Patient demographics, clinical information and associated mycology are shown in Table 2 .

Fifty-one of the 135 patients (37·8%. 95% CI: 30·0-46·2) had ≥1 positive mycological test (culture, BDG, GM-EIA or PCR) ( Table 2) . Seventeen patients (12·6%, 95% CI: 8·0-19·2) had evidence of invasive yeast infection, mainly (93·8%) Candida (Table 3 ). There was one case of Rhodotorula fungaemia. Thirty patients (22·2%, 95% CI: 16·0-30·0) had ≥1 Aspergillus positive results, 14 having just a single positive result and 16 having ≥2 Aspergillus positive results (Table 4 ). In addition, four patients, potentially with unspecified IFD, were BDG positive on multiple occasions. There were no documented cases of Pneumocystis pneumonia.

Sample and patient positivity rates for the primary diagnostic investigations are shown in table 2 and 

There was a significant association between patients with positive mycology and patients diagnosed with or treated for a solid malignancy (Table 1) . Among the 57 patients where corticosteroids data was available, there was a strong association between patients with multiple Aspergillus/BDG (≥2) positive results and the use of high-dose systemic corticosteroids (13/15 patients, Odds ratio 7.9, 95% CI: 1.6-39.3, P: 0·007), compared to 19 of 42 with ≤1 positive result. There was a significant association for patients with an underlying chronic respiratory condition to have multiple positive Aspergillus/BDG tests (7/16) compared to 23/116 patients without multiple positive results (OR: 3·15, 95% CI: 1·06-9.34, P: 0·05). There were no significant associations between underlying conditions/co-morbidities and yeast infections (results not shown).

Procalcitonin, C-reactive protein, total leucocytes, neutrophils and lymphocytes were similar across cohorts ( Table 1) . (Table 2) .

In 7/16 of patients with multiple Aspergillus positive results CT-Thorax/CTPA was non-specific, indicative of progressing respiratory infection and indistinguishable from COVID-19 pneumonia (e.g. bilateral airspace opacification). However, in 56% chest CT was typical of IPA (cavities (n=5), nodules (n=5) and "tree in bud" (n=1)) ( Table 4) . Seven patients had one typical chest sign and two patients A c c e p t e d M a n u s c r i p t 8 had two signs. Three patients (6, 14 and 16 in table 4) had potential bacterial respiratory infection possibly explaining the CT evidence, although each patient had 3-5 mycological positive tests supportive of IPA. Four patients with typical chest radiology also had CT evidence of sinusitis. One additional patient with non-specific chest radiology had evidence of sinusitis. In total, 62.5% of patients with multiple Aspergillus positive tests had radiology that could be attributed to IFD.

Of the 14 patients with a single Aspergillus positive test two had nodules and one patient had evidence of sinusitis. One patient had Aspergillus cultured from a NBL, with a GMI of 0·5, another was Aspergillus PCR positive on NBL and the third had a single NBL with a GMI of 1·0, but also had a potential bacterial pneumonia and likely lung metastases. None of the patients received antifungal therapy and two died. Two of the four patients that were positive by BDG alone had radiological evidence (one potential fungal ball in the sinuses, one lung nodule). Two of the 84 patients who were negative for mycology had evidence of chest cavitation.

Comparing the chest radiology typical of IPA from patients with multiple Aspergillus positive results (n=16) to those with yeast infection (radiology typical of IPA: 0/17) combined with patients with negative mycology (radiology typical of IPA: 2/84) generates sensitivity and specificity of 56.3% (95% CI: 33.2-76.9) and 98·0% (95% CI: 93·1-99·5), respectively. The subsequent positive likelihood ratio (28.2) was highly predictive of IPA (probability: 82·2% at a 14.1% incidence).

The incidence of IPA varies, dependent on the definitions used to classify disease (Tables 1 and 4 ).

Using the AspICU, IAPA and novel CAPA definitions the incidence of IPA was 5·9% (8/135), 14·8%

(20/135) and 14.1% (19/135), respectively. [2, 22] Between the three methods 25 patients were classified with IPA ( Table 4 ). The eight patients classified by the AspICU definitions were supported by the IAPA definitions, but one patient was not classified using the CAPA definitions. This patient had Aspergillus fumigatus cultured from a single NBL sample but radiology was non-specific. Seven of the 12 additional IPA cases classified by IAPA were supported by CAPA, five had radiology A c c e p t e d M a n u s c r i p t 9 attributable to IPA and two had non-specific radiology, all were supported with multiple Aspergillus positive results (Table 4 ). Three patients classified by IAPA alone had non-specific radiology with a single Aspergillus positive result. Two patients had radiology that could be attributed to IFD (one sinusitis and one nodules), both had a single supporting mycology result. Given the broad aetiological diversity associated with sinusitis, including COVID-19, the lack of multiple positive Aspergillus markers prevented classification using the CAPA definitions ( Table 1 ). The patient with nodules had secondary lung metastases and a bacterial pathogen, possibly explaining the radiology;

subsequently multiple positive Aspergillus results would be required to classify CAPA. Of the five IPA patients classified by CAPA alone, two had nodules detected on chest CT with supporting mycological evidence and two had non-specific radiology but multiple Aspergillus positive results.

The final patient had radiological evidence of a fungal ball in the sinuses and was supported by multiple strongly positive BDG results.

The overall mortality rate for COVID-19 patients on ICU was 38% (Table 1) . Mortality rates in patients with negative mycology were similar irrespective of AFT (P: 1·000). The mortality rate in patients defined with CAPA was 57.9% (95% CI: 36.3-76.9), ranging from 46.7% (95% CI: 24.8-69.9) in patients receiving appropriate AFT to 100% (95% CI: 51.1-100) in patients not receiving appropriate AFT. In patients with invasive yeast infection mortality was 47·1% (95% CI: 26·2-69·0), ranging from 27·3% (95% CI: 9.8-56.6) in patients on appropriate AFT to 83·3% (95% CI: 43.7-97.0) in those not receiving appropriate AFT (P: 0.0498). For combined IFD (CAPA and yeast infections) the mortality rate was 52.8% (95% CI: 37.0-68.0), being 38.5% (95% CI: 22.4-57.5) in patients receiving appropriate AFT and 90.0% (95% CI: 59.6-98.2) in those not receiving appropriate AFT (P: 0.008). All four patients with unspecified IFD died, two received appropriate AFT.

A c c e p t e d M a n u s c r i p t

There is urgent need for structured IFD testing in COVID-19 patients given the likely poor prognosis in untreated patients. [5, 10, 12] BDG was incorporated as a primary test as it provides broad-fungal detection in easily obtainable samples and has been associated with improved sensitivity over serum GM-EIA testing for the diagnosis of ICU associated IPA.

[23] Unfortunately, BDG testing is not universally available and while GM-EIA screening of blood is highly specific it cannot be used to exclude CAPA, leaving the testing of respiratory samples as the preferred option. While testing BAL would be preferable, obtaining this invasive sample from a large number of COVID-19 patients represents a significant infection control risk. Obtaining NBL is less intrusive and is a routine microbiological investigation in many Welsh ICU units. Mycological testing of NBL is less validated and could be associated with the detection of upper airway fungal colonization/contamination, but a recent evaluation in COVID-19 supports NBL fungal testing and there is an argument for a low threshold for initiating AFT, given early AFT significantly improves prognosis of IA. [24, 25] In this study the mortality rate of IFD patients on appropriate AFT (38.5%) was comparable to patients suffering from COVID-19 alone (31.0%).

The incidence of CAPA varied according to the definitions applied (Table 1) . Using the definitions proposed in this manuscript, the CAPA incidence was 14.1% of patients screened (7.4% of all COVID-19 ICU admissions), lower than two previous studies in France (30%) and Germany (26%). Patient numbers in this current study were 5-7 fold higher and its prospective, consecutive multicentre nature should provide more robust data, although geographical differences need to be considered.

[10,11] A limitation of our study is that not all ICU patients were screened, and of those that were <50% were tested by the optimal combined respiratory/circulatory approach. Consequently, the incidence of CAPA is likely underestimated, nevertheless considerable. While 257 COVID-19 patients were admitted to the ICU during the testing period, not all would have met the inclusion criteria A c c e p t e d M a n u s c r i p t 11 ( Figure 1 ), so calculating incidence based on all patients, or extrapolating the incidence to entire population to determine a total disease burden would not be accurate. Given 68.4% and 84.2% of CAPA defined cases were positive by serum BDG and NBL testing, respectively, it is possible that CAPA cases were missed when combination testing was not performed, accounting for this increases the incidence to 31%, in line with other studies. [10, 11, 26] The AspICU definitions significantly underestimate the rate of CAPA (5·9%), with classification based on respiratory culture that lacks sensitivity, is slow and of limited utility in the ICU, with mortality rates similar in patients with positive Aspergillus respiratory culture, irrespective of AFT.

[27]

Applying the IAPA definitions, which incorporate GM-EIA, increases the incidence to 14·8%, similar to the proposed CAPA definitions (14.1%), but considerable discordance was evident (Table 4 ). Given the IAPA definitions allow non-specific radiology with a single GM-EIA positive result it is hoped that the CAPA definitions would provide enhanced specificity. Overall mortality rates from cases classified according to the CAPA and IAPA definitions were 58% and 45%, respectively, 46·7% of CAPA patients died despite AFT, while 100% not receiving AFT died. In IAPA defined patients, 42·9% died on AFT and 50% died while not receiving AFT. As a high mortality would be expected in untreated IPA patients, it appears that the IAPA definitions are misclassifying patients. While this could be a result of testing NBL over BAL, the utility of NBL testing has been demonstrated. [25] Receiver operator characteristic analysis of NBL GM-EIA testing, with CAPA defined using the proposed definitions showed that using GM threshold of 1.2 generated a specificity of 97.4%, with values >4.5 associated with 99% specificity, implying a high likelihood of IPA (Positive likelihood ratio >16) and performance comparable to BAL testing.

[28] In patients with no mycological evidence of IFD, the use of AFT did not improve patient outcome indicating that the CAPA definitions were not missing cases. The prognosis of untreated CAPA is unclear, sub-acute or chronic disease could occur in this heterogeneous group. The overuse of AFT is obviously of concern, but the incidence of CAPA was not excessive, and the administration of AFT on the basis of radiology typical of IPA or positive A c c e p t e d M a n u s c r i p t 12 mycology represents an improvement over empirical AFT use (29% of mycology negative patients in this study received empirical AFT, without improving prognosis).

CT of the chest and head provided signs that could be attributed to IFD in 15 patients. However, many patients presented with non-specific radiology, which makes diagnosing an additional respiratory infection in a patient with underlying respiratory disease challenging. In this scenario, progression of non-specific radiology can be suggestive of IFD. Chest signs more typical of IA are highly specific (98%) and should increase concern of IA, unless they can be attributed to alternative clinical reason (e.g. lung metastases).

[29] Given the variability in reporting of chest radiology, independent review of images by a radiologist with experience of discriminating IFD is recommended.

Clinical risk factors associated with CAPA included an underlying chronic respiratory condition and the use of corticosteroids. The latter has implications in the UK COVID-19 treatment randomized control trial where one arm recommends the use of dexamethasone, which been associated with reduced COVID-19 mortality (RECOVERY trial, www.recoverytrial.net). Adverse outcomes in this arm could be potentially attributable to CAPA rather than COVID-19, and the benefits of this approach could be enhanced if CAPA was systematically screened for and treated. In 31 COVID-19 patients requiring ventilator support on ICU in the Netherlands the incidence of putative CAPA was (10%).

[30] In this current study, 79% of CAPA patients were ventilated. As noted previously, there was a significant incidence of invasive yeast infections (13%).

[31] The reasons for this are unclear, but may be a consequence of difficult working conditions, rather than COVID-19. Given cases of IFD present 1-5 weeks post ICU admission frequent and prolonged testing of easily obtained specimens is recommended.

To conclude, there is substantial IFD in ICU-COVID-19 patients, potentially associated with poorer prognosis. The proposed systematic screening programme using a combination of markers from easily obtainable samples provides a sufficiently sensitive and specific way of identifying IFD in patients with COVID-19 and has the potential to reduce mortality from this relatively frequent A c c e p t e d M a n u s c r i p t 24 A c c e p t e d M a n u s c r i p t M a n u s c r i p t 43 Figure-1 

Predicting Invasive Aspergillosis in Hematology Patients by Combining Clinical and Genetic Risk Factors with Early Diagnostic Biomarkers

Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study

Oseltamivir affects host defense against invasive pulmonary aspergillosis

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Diagnosing COVID-19-associated pulmonary aspergillosis

Pre-empting and mitigating the risk that invasive pulmonary fungal infections present to patients with COVID-19

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Hoenigl M COVID-19 Associated Pulmonary Aspergillosis

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

A c c e p t e d M a n u s c r i p t M a n u s c r i p t